Big Pharma Can't Stop Shopping in China

That narrative is dead.

Chinese biotech companies now have a rapidly growing pipeline, and their drug candidates represent a significant share of innovative drugs globally. They lead the world in antibody-drug conjugates (ADCs), which are like guided missiles that deliver chemotherapy directly to cancer cells.

When Jefferies analysts crunched the numbers, they found that Chinese assets accounted for 32% of all out-licensing value in Q1 2025, up from 21% in 2023-2024.

Nearly every major Western pharma company is now in the game. Gilead, AbbVie, GSK, Pfizer, Merck, Amgen; the list reads like a who's who of Big Pharma's corner offices.

Why the Frenzy? Patent Cliffs and Speed

Western pharma has a looming problem: patent cliffs. Blockbuster drugs are losing exclusivity, and internal R&D pipelines can't fill the gap fast enough. Developing a drug from scratch in the US takes years and costs billions. Chinese biotechs offer a shortcut.

Consider the speed difference. Clinical trials in China are widely recognized as significantly faster than in the US. When you're racing to replace revenue from expiring patents, that time savings is worth a fortune.

The deals reflect this urgency. Average upfront payments climbed from $102 million in 2024 to $141 million in 2025. Chinese biotechs aren't getting lowball offers anymore. Western companies are paying premium prices because the assets justify it.

Full-year 2025 numbers paint the big picture: deals worth $135.7 billion, a significant increase over 2024. And early 2026 is on pace to blow that away.

The Elephant in the Room: Geopolitics

Of course, there's a catch. US-China relations aren't exactly in a golden era. The BIOSECURE Act, passed as part of the FY2026 US defense bill, bans federal agencies and contractors from using services provided by designated Chinese "biotechnology companies of concern." January 2025 brought new export controls on biotech equipment like flow cytometers. The regulatory walls are getting higher.

And yet, the deals keep flowing. The volume of agreements between Western and Chinese firms has continued to grow year over year.

The math is straightforward: Western pharma needs what Chinese biotechs are selling. Geopolitical risk is real, but so are patent cliffs. For now, the need is winning.

What Happens Next

Analysts see this trajectory accelerating, not slowing. The so-called "bargain era" is ending as Chinese firms recognize the value of their assets and build their own global commercialization capabilities. Some experts predict that Chinese pharma companies will eventually skip the licensing step entirely and sell drugs worldwide on their own.

That would be the ultimate plot twist: the supplier becomes the competitor.

For Western pharma, the message is clear. The window to lock up Chinese innovation at favorable terms is narrowing. Every quarter of delay means higher prices, fewer available assets, and more competition from other multinationals scrambling for the same programs.

The billions spent in January and February wasn't just a shopping spree. It was a signal that the center of gravity in drug discovery is shifting eastward, and Big Pharma is placing its bets accordingly.

Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of

Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.